As the Novel Coronavirus is an emerging pathogen, neither the EPA nor Health Canada have an approved test method for determining or allowing disinfectant efficacy product label claims. In cases of Emerging Pathogens such as 2019-nCoV, the EPA implements the Emerging Viral Pathogens Guidance for Antimicrobial Products. This guidance utilizes an organism hierarchy to identify effective products for use with emerging pathogens and to permit registrants to make limited statements against such pathogens. Coronaviruses are enveloped viruses that are among the easiest organisms for disinfectants to kill or inactivate. The following criteria is used to determine the efficacy of a disinfectant upon activation of the Emerging Pathogen rule: 1. The product must be a hospital or broad-spectrum disinfectant product registered with EPA. 2. For an emerging enveloped virus, the product must have acceptable efficacy data previously submitted to and reviewed by the Agency against one non-enveloped virus (Poliovirus).

The Rejuvenate™ line of disinfectants (concentrate, ready-to-use, and premoistened wipes) have demonstrated effectiveness against viruses similar to 2019-nCoV on hard, nonporous surfaces. Therefore, the Rejuvenate™ line of disinfectants can be used against 2019-nCoV when used in accordance with the directions for use against Poliovirus type 1 on hard, non-porous surfaces. Refer to the CDC website at www.cdc.gov/outbreaks/ for additional information.